RAPT Key Statistics, Chart & Performance
The current stock price of RAPT is 57.62 USD. In the past month the price increased by 60.77%. In the past year, price increased by 531.8%.
RAPT Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to RAPT. When comparing the yearly performance of all stocks, RAPT is one of the better performing stocks in the market, outperforming 99.45% of all stocks.
RAPT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RAPT. RAPT has a great financial health rating, but its profitability evaluates not so good.
RAPT Financial Highlights
Over the last trailing twelve months RAPT reported a non-GAAP Earnings per Share(EPS) of -11.06. The EPS increased by 50.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -63.74% | ||
| ROE | -69.51% | ||
| Debt/Equity | 0 |
RAPT Forecast & Estimates
17 analysts have analysed RAPT and the average price target is 63.14 USD. This implies a price increase of 9.58% is expected in the next year compared to the current price of 57.62.
RAPT Ownership
RAPT Latest News, Press Relases and Analysis
About RAPT
Company Profile
Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company is headquartered in South San Francisco, California and currently employs 60 full-time employees. The company went IPO on 2019-10-31. The firm is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.
Company Info
RAPT THERAPEUTICS INC
561 Eccles Ave
South San Francisco CALIFORNIA 94080 US
CEO: Brian Wong
Employees: 60
Phone: 16504899000
RAPT THERAPEUTICS INC / RAPT FAQ
Can you describe the business of RAPT THERAPEUTICS INC?
Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company is headquartered in South San Francisco, California and currently employs 60 full-time employees. The company went IPO on 2019-10-31. The firm is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.
Can you provide the latest stock price for RAPT THERAPEUTICS INC?
The current stock price of RAPT is 57.62 USD.
What is the dividend status of RAPT THERAPEUTICS INC?
RAPT does not pay a dividend.
What is the ChartMill technical and fundamental rating of RAPT stock?
RAPT has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is RAPT stock listed?
RAPT stock is listed on the Nasdaq exchange.
What is the Price/Earnings (PE) ratio of RAPT THERAPEUTICS INC (RAPT)?
RAPT THERAPEUTICS INC (RAPT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-11.06).
Can you provide the upcoming earnings date for RAPT THERAPEUTICS INC?
RAPT THERAPEUTICS INC (RAPT) will report earnings on 2026-03-04, after the market close.